Children's Hospital, Zhengzhou University
河南省儿童医院(郑州儿童医院)
Listed for 12 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Children's Hospital, Zhengzhou University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Retinoblastoma视网膜母细胞瘤1 paper led
- Osteosarcoma骨肉瘤2 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
- Neuroblastoma神经母细胞瘤9 papers led
- Fanconi anaemia范可尼贫血0 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
- Fabry disease法布雷病0 papers led
- Duchenne muscular dystrophy杜氏肌营养不良1 paper led
- Behçet disease白塞病0 papers led
- Alport syndromeAlport 综合征0 papers led
- Osteogenesis imperfecta成骨不全症0 papers led
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Hepatoblastoma, Chordoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Pompe disease, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Retinoblastoma
视网膜母细胞瘤Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Zhengzhou for retinoblastoma176 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led1
All its trials on ClinicalTrials.gov, any status1
Cancer
Osteosarcoma
骨肉瘤Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Zhengzhou for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led2
- Demethylzeylasteral inhibits osteosarcoma cell proliferation by regulating METTL17-mediated mitochondrial oxidative phosphorylation.
- Downregulation of CDC20 suppressed cell proliferation, induced apoptosis, triggered cell cycle arrest in osteosarcoma cells, and enhanced chemosensitivity to cisplatin.
Earlier papers (2016–2020)1
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Zhengzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Cancer
Neuroblastoma
神经母细胞瘤Led 9 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Zhengzhou for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led9
- The causal relationship between immune cells and neuroblastoma: a Mendelian randomization study.
- Enzymatically Cyclic Activated Biosensor Based on a Tetrahedral DNA Framework for Precise Tumor in Situ Molecular Imaging.
- Joint metabolomics and transcriptomics analysis systematically reveal the impact of MYCN in neuroblastoma.
- Plasma circulating cell-free MYCN gene: A noninvasive and prominent recurrence monitoring indicator of neuroblastoma.
- CCNB1IP1 prevents ubiquitination-mediated destabilization of MYCN and potentiates tumourigenesis of MYCN-amplificated neuroblastoma.
- Metabolomics-transcriptomics joint analysis: unveiling the dysregulated cell death network and developing a diagnostic model for high-grade neuroblastoma.
- A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle.
- Joint analysis of the metabolomics and transcriptomics uncovers the dysregulated network and develops the diagnostic model of high-risk neuroblastoma.
- Dual isothermal amplification all-in-one approach for rapid and highly sensitive quantification of plasma circulating MYCN gene of neuroblastoma.
Blood disorders
Fanconi anaemia
范可尼贫血Led no English-language PubMed papers on Fanconi anaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Zhengzhou for Fanconi anaemia40 hospitals in China for Fanconi anaemia
No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Zhengzhou for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Chinese-language papers (not in the count)1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Zhengzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Other diseases
Fabry disease
法布雷病Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Zhengzhou for Fabry disease80 hospitals in China for Fabry disease
No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Zhengzhou for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Other diseases
Behçet disease
白塞病Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Zhengzhou for Behçet disease139 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Chinese-language papers (not in the count)1
Other diseases
Alport syndrome
Alport 综合征Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Zhengzhou for Alport syndrome60 hospitals in China for Alport syndrome
No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)1
Other diseases
Osteogenesis imperfecta
成骨不全症Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Zhengzhou for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta
No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Getting in touch
Name card to show staff or a driver
河南省儿童医院(郑州儿童医院)
Children's Hospital, Zhengzhou University
郑州
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
No hospital-level ROR record matched.